Form 4: Climb Bio Director Drapkin Acquires 80,000 Stock Options

Kimberlee C Drapkin, a director of Climb Bio, Inc., acquired 80,000 stock options on March 28, 2025, according to a Form 4 filing.

Summary

• Kimberlee C Drapkin, a director of Climb Bio, Inc. (CLYM), filed a Form 4 with the SEC.
• The filing reports a transaction on March 28, 2025, where Drapkin acquired 80,000 stock options.
• The exercise price of the options is $1.28.
• The options vest in equal monthly installments from March 28, 2025, until the third anniversary, subject to continued service.
• The expiration date of the options is March 27, 2035.
• Following the transaction, Drapkin directly owns 80,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of stock options by a director could be seen as a positive sign, but without further context, it's difficult to assess the overall impact.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates Drapkin's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future prospects.

Key Dates

Keywords

Form 4, stock options, director, CLYM, Climb Bio, Drapkin, acquisition